Drugs / Dalutrafusp alfa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03954704 | Jun 2019 → Oct 2020 | cancer | Gilead Sciences | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dalutrafusp alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03954704 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5095272 ↗ |
| Route | Intravenous | “Administered intravenously” NCT03954704 ↗ |